Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 52%
Buy 33%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

DexCom reported a robust 22% year-over-year growth in international revenue and a 21% increase in domestic revenue, highlighting its successful penetration into the Type 2 diabetes (T2D) market and burgeoning international markets like France and Canada. The company's upward revisions in sales guidance to $4.630B-$4.650B, reflecting a projected 15% year-over-year growth, underscore its strong performance and expected continued momentum from Medicare expansion and additional coverage wins. Furthermore, key innovations and a focus on remote monitoring are anticipated to enhance growth potential, reinforcing a favorable long-term outlook for the company's financial performance.

Bears say

DexCom's revised profitability outlook and a decline in gross margins signal potential challenges ahead, with adjusted EBIT and EBITDA expectations facing downward revisions. The company reported its first non-record new patient quarter in a significant timeframe, raising concerns about the impact of quality issues on business performance amidst increasing competition and integration of competitor products such as the Libre. Additionally, the forecasted growth rates for sensor revenue have been downgraded, reflecting anticipated pressures from both competitive dynamics and operational challenges, including increased scrap rates and rising operating expenses.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 52% of analysts recommend a Strong Buy, 33% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.